India, July 17 -- AbbVie Inc.'s (ABBV) Allergen Aesthetics, on Friday said it gained European Commission's approval for Boey to treat moderate-to-severe glabellar lines between eyebrows in adults, when the condition has an important psychological impact.
The approval applies across all 30 countries in the European Economic Area following completion of the centralized review procedure. Boey also received regulatory approval in Canada in June.
Boey is a rapid-onset, short duration facial injectable botulinum neurotoxin serotype E designed to target SNAP-25.
The approval was supported by two randomised, placebo-controlled Phase 3 trials, M21-500 and M21-508, in adults with moderate to severe glabellar lines associated with corrugator and/or...